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ments. In addition, diabetic patients with low education level cost 2.341€ cost more 
on average in comparison to better educated patients. ConClusions: T2DM is an 
expensive to treat disease and in the era of limited resources and escalating costs 
it is critical to implement sound public health policies in order to achieve patient’s 
good glycemic control and consequently less burden to health care budgets.
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objeCtives: To calculate the cost of illness (COI) associated with adrenal insuffi-
ciency (AI) in the UK. AI patients do not produce cortisol and require glucocorticoid 
replacement therapy (RT) to survive, which is predominantly immediate-release 
hydrocortisone in the UK. With current therapy, AI patients have increased mor-
bidity and premature mortality, and suffer reduced quality-of-life. Methods: The 
COI determines the direct and indirect costs over a 1-year period. The COI includes 
the cost of RT, primary and secondary care costs (GP and outpatient appointments; 
admissions for adrenal crises; diagnosis and management of AI) and those associ-
ated with reduced productivity (absenteeism). Direct costs were estimated using 
national reference costs, Payment by Results tariffs and other published data. AI 
prevalence and adrenal crises data were taken from published literature and activity 
data (hospital admissions for management of AI) from Hospital Episode Statistics 
(HES) data. A 2012 worldwide survey of AI patients was used to determine days 
taken off work and clinical expert opinion was sought to determine total outpatient 
appointments per year. The costs associated with premature mortality, the treat-
ment and management of co-morbidities and the burden associated with reduced 
quality of life were not included due to lack of data. Results: There are ~20,000 AI 
patients in the UK. Based upon the burden of disease calculations, the estimated 
COI associated with AI is £1,922 per patient or £39.7 million over 1 year: RT, £21.7 
million; GP appointments, £1.8 million; secondary care, £4.4 million; and reduced 
productivity, £11.8 million. ConClusions: The high health care and social costs 
associated with AI highlight the clinical and economic need to improve RT. Indeed, 
as some consequences of the disease were not included in the calculations, £39.7 
million is likely a considerable underestimate of the true burden of disease.
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objeCtives: To assess the direct costs associated to type I and II diabetes mellitus 
(DM) from a health care perspective in Spain. Methods: We performed a cost of ill-
ness study considering the prevalence approach. The use of resources was estimated 
from the existing Spanish health care databases and bibliographic references. Costs 
evaluated were: hospital costs (including outpatient care), primary care costs, drugs 
costs, consumables costs and additional tests costs. All costs were updated to 2012 
euros. Results: The total direct annual cost of DM was 5,809 million euros repre-
senting 8.2% of the total Spanish health expenditure. The total drug cost accounted 
for 2,232 million euros (38%) and was mainly due to the elevated contribution of 
non-antidiabetic drugs (24%). Hospital costs represented 1,934 million € (33%) and 
were mainly driven by the acute and chronic complications (17%). Cardiovascular 
disease cost (521 million € ) and peripheral vascular disease costs (127 million € ) 
were the most important complications cost drivers. The contribution of monitoring 
strips to the total cost was only 118 million € (2%). Total complications cost repre-
sented 2,143 million € (37% of the total direct cost). ConClusions: DM total direct 
costs are strongly conditioned by DM complications cost and have a considerable 
economic impact on Spanish health expenditure. In order to reduce the health and 
economic impact generated by DM, the introduction of measures and strategies 
focused on improving the efficiency of the treatment of the disease are crucial.
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objeCtives: There have been a number of studies quantifying the direct and indi-
rect resource implications associated with severe hypoglycaemia episodes (SHE) 
and non-severe hypoglycaemia episodes (NSHE). The objective of this study was to 
calculate the total direct and indirect economic burden associated with SHE and 
NSHE in insulin treated type 2 diabetes mellitus (T2DM) subjects. Methods: We 
conducted two literature reviews of the MEDLINE database for studies published 
between June 1, 2007 and June 1, 2012. The first assessed the direct (primary and 
secondary care and treatment related) and indirect resource implications (lost pro-
ductivity) associated with SHE and NSHE; the second established the frequency of 
NSHE and SHE in insulin-based clinical trials where sulfonylurea usage was also 
reported in T2DM. An economic model written in Microsoft Excel was developed to 
predict the expected annual per-patient cost (using 2011 US costs) associated with 
the incidence of hypoglycaemia. Results: Resource utilisation from 6 studies and 
data characterising hypoglycaemia frequency were extracted from 82 studies for a 
total of 155 trial arms where the search criteria were met. Mean annual hypoglycae-
mia event rates were 16.4, 8.9, 4.8 and 2.6 for NSHE and 0.083, 0.039, 0.015 and 0.003 
for SHE associated with baseline HbA1c levels of 6%, 7%, 8% and 9% respectively.
Total expected annual per-patient hypoglycaemia costs were $929, $471, $237 and 
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objeCtives: Severe hypoglycaemias occurring in diabetes care are associated with 
a major economic burden on health care systems, with a major part of the direct 
costs resulting from the small proportion of patients who are admitted to hospital. 
We assessed the inpatients costs of severe hypoglycaemic events in Type 1 and 2 
diabetes (SHE) patients in France. Methods: The study was done using the 2012 
French National Database on hospital care (PMSI). This comprehensive database 
covers all hospital stays in the French population (over 20 million hospital stays per 
year). SHE were identified using ICD10 codes of hypoglycaemias (E160, E161, E162, 
T383) in combination with diabetes codes (E11, E10, E13, E14, N083) and excluding 
gestational diabetes. Directs costs to the health care system were estimated using 
the French National Costs study (2011 values). Results: Overall, in 2012, 17,835 
stays for diabetes related hypoglycaemias were identified in the database corre-
sponding to 16,406 patients. 8.7% of patients were hospitalized twice in the year for 
SHE, 51% were male and aged 66.7 years on average (SD 19.7). 90% of stays occurred 
in public hospitals and mean length of stay was 8.1 days (median 7.0). The mean 
direct cost of one SHE hospital stay was € 4,360. Extrapolated to the whole country 
the direct cost of hospitalized SHE was € 77.7 million which roughly correspond to 
1.2% of the overall diabetes costs for the health care system. Such value would be 
considered a conservative estimate due to potential underreporting of cases in the 
database. ConClusions: Our study confirmed that hypoglycaemic events lead to 
substantial costs for the community even it was limited to direct costs in inpatient 
setting. As the short-term and long term consequences of hypoglycaemia begin to 
be better understood, more studies have to be done to estimate the full economic 
burden of this disease.
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objeCtives: Health expenditure to treat and prevent T2DM and its complications 
was estimated at USD 345 million for OECD countries in 2010. These costs pose 
great burden to national health system’s budget, which is already under pres-
sure. In Greece there are no studies that provide information on the costs of T2DM 
patients including the cost of complications, hospitalizations and co-morbidities. 
The current study aimed to estimate the total cost of T2DM patients from a third 
party payer perspective. Methods: A retrospective research study was performed 
in four major hospital diabetes centers and 211 patients with at least 10 years 
of T2DM from diagnosis. Patients were categorized in two groups, controlled and 
uncontrolled. Hospitalization and management of complications was based on DRG 
cost. Pharmaceutical and diagnosis cost was based on official NHS prices. Health 
care cost corresponds to 2012 Euros and the perspective used was of the Social 
Security Fund. Subgroup analysis was performed in order to evaluate the cost dif-
ference between controlled vs. uncontrolled, obese non-obese and various other 
subgroups. Results: The mean age of patients was 72.9±8.1 years with mean T2DM 
duration 21.2±7.5 years, and mean HbA1c 7.3±1.0%. The mean average yearly cost of 
T2DM was € 7.111 whereas only the18.8% was attributed to cost of antidiabetic drugs. 
Controlled patients (HbA1c ≤ 7) cost on average 6.366 and uncontrolled (HbA1c> 7) 
€ 7.783. The mean hospitalization and complication cost was € 2.456. It was found 
no difference of mean hospitalization and complication cost between controlled 
and uncontrolled patients (p= 0.09). Co-morbidities cost absorbs the majority of the 
budget and was the differentiating factor between two groups. Few patients (21.8%) 
reported admission to hospital with similar hospitalization rates on number and 
duration between the two groups. ConClusions: T2DM is an expensive to treat 
disease with very high cost complications with economic and societal burden.
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objeCtives: Health expenditure to treat and prevent T2DM and its complications 
was estimated at USD 345 million for OECD countries in 2010. These costs pose a 
great burden to the national health system’s budget, which is already under pres-
sure. In Greece there are no studies that provide information on the costs of T2DM 
patients including the cost of complications, hospitalizations and co-morbidities. 
The current study aimed to estimate the total cost of T2DM patients from a third 
party payer perspective. Methods: A retrospective research study was performed 
in four major hospital diabetes centers and 211 patients with at least 10 years 
of T2DM since diagnosis. Patients were categorized in two groups, controlled and 
uncontrolled. Hospitalization and management of complications was based on DRG 
cost. Pharmaceutical and diagnosis cost was based on official NHS prices. Health 
care cost corresponds to 2012 Euros and the perspective used was of the Social 
Security Fund. Subgroup analysis was performed in order to evaluate the cost differ-
ence between controlled vs. uncontrolled, obese non-obese and various other sub-
groups. Results: The mean average yearly cost of T2DM was € 7.111 whereas only 
18.8% was attributed to cost of antidiabetic drugs. Diabetic men cost 2.222€ more per 
year in comparison to diabetic women, whereas obese diabetics cost 1.460€ more 
per year in comparison to overweight and normal patients. These may be explained 
by the higher levels of HbA1c, co-morbidities and the number of antidiabetic treat-
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cular complications- 41%. In the type 1 diabetes group the cost was equal to 15 364 
EUR with the following split: 63% due to (general) diabetes, 19% due to microvascular 
complications, and 18% due to macrovascular complications. ConClusions: Type 
2 diabetes is more costly than type 1 when hospitalizations occur. People with type 
2 diabetes pay high cost for macrovascular complications than for microvascular 
probably due to high hypertension prevalence. The difference in costs between type 
1 and 2 may result from different patients’ characteristics.
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objeCtives: Due to the preparation for the transition to health insurance in Ukraine 
and because of the significant increase in thyroid disease it is important to assess a 
range of medicines included to the Ukrainian National Formulary (UNF). Methods: It 
was compared the range of drugs for treatment of thyroid disease which are included 
to the Ukrainian National Formulary with the WHO Model list of Essential Medicines. 
Also it was calculated the annual cost of treatment by each medication considering 
the usual maintenance dose. Results: In accordance to WHO Model List of Essential 
Medicines it was established that Ukrainian National Formulary includes thyroid 
hormones and antithyroid medicines for thyroid disease treatment such as: levothy-
roxine sodium and potassium iodide. Also it was found that there are no propylthi-
ouracil medications in UNF. The dosage of levothyroxine sodium tablets satisfies the 
norms of World Health Organization, which are: 25 micrograms, 50 micrograms and 
100 micrograms. Potassium iodide tablets in dose of 100 micrograms, 200 micrograms, 
1 mg does not comply the norm. According to WHO Model list of Essential Medicines 
dosage of potassium iodide in tablets should be 60 mg. The cheapest annual cost of 
treatment by levothyroxine per patient is EUR 10,95 (The EUR/UAH conversion rate: 1 
EUR = 10,52 UAH (Average 2013)), the most expensive is EUR 80,30. The most expensive 
annual cost of treatment by potassium iodide per patient is EUR 31,32, the cheapest is 
EUR 2,85. ConClusions: Propylthiouracil should be included to Ukrainian National 
Formulary. The cost difference of thyroid disease treatment by essential medicines 
caused by presence of foreign products in the pharmaceutical market of Ukraine.
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objeCtives: The randomized controlled ABACUS study assessed the impact of 
using the automated insulin bolus advisor within the Accu-Chek Aviva Expert sys-
tem in combination with intensive diabetes therapy on glycemic control in patients 
treated with MDI therapy. This analysis assessed the potential incremental eco-
nomic benefit of using this automated bolus advisor device on the short-term health 
care costs (SHC). Methods: The study outcome parameter was “achieving the goal 
of an at least 0.5% reduction in HbA1c”. The economic analysis was performed with a 
spreadsheet-model from a UK payer’s direct cost perspective and based on ABACUS 
outcomes. Data on correlation between HbA1c change and expected cost are based 
on published literature. Model outputs include expected impact on SHC and sen-
sitivity analysis. Results: A total of 56% of patients in the intervention group (IG) 
achieved the goal, in the control group (CG) 34% respectively. Goal achievement led 
to an average HbA1c reduction of 1.2%, irrespective of group. There was no clinically 
relevant HbA1c effect in the remaining patients. Goal achievement correlates with 
an expected reduction in SHC of £189 per person / per year (PPY). The expected 
SHC reduction is £104 PPY in the IG and £74 PPY in the CG. The goal-achievement-
rate increased by 63%, driving a comparative economic benefit of £30 PPY for an 
automated insulin bolus advisor supported approach. There were no significant dif-
ferences in complications or in intervention cost. ConClusions: An MDI therapy 
in diabetes care that is supported by the Accu-Chek Aviva Expert systems with its 
automated bolus advisor leads to a 63% higher rate of goal achievement. This is 
expected to result in an incremental reduction in short-term health care costs of 
£30 PPY. Hence automated bolus calculation improved the cost-effectiveness of 
self-monitoring of blood glucose in this study population.
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objeCtives: Type 2 diabetes mellitus (DM) is widely spread in Russia, counting 
about 10 million. New drugs are highly effective and carry a high cost for health 
care. The results of clinical trials are not enough to assess long term efficacy 
and safety of treatment. Modeling is a tool for making long term economic and 
outcome prognosis and comparing treatment strategies. The main goal of the pre-
sented study was to develop a predictive model of type 2 DM outcomes validated 
in Russian clinical conditions and to perform pharmacoeconomic evaluation of 
glucose lowering therapies. Methods: Existing type 2 DM models were evalu-
ated. Risk equations for type 2 DM complications were compiled from EAGLE and 
UKPDS DM models. Demographic (age, sex, height, weight, DM duration, smok-
ing), biochemical (HbA1c, lipids) and clinical (blood pressure) patient parameters 
were used as inputs. Glucose lowering drug effectiveness was incorporated into 
$117 associated with HbA1c levls of 6%, 7%, 8% and 9% respectively. ConClusions: 
In insulin treated T2DM subjects lower HbA1c is associated with higher frequency of 
hypoglycaemia and associated costs. Failing to account for the cost burden associ-
ated with hypoglycaemia may underestimate the value of diabetes management 
strategies that minimize hypoglycaemia risk.
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objeCtives: To assess the cost and metabolic outcomes in children with diabetes 
mellitus treated with CSII or with human insulin. Methods: It is a cost-conse-
quence analysis. Retrospectively were observed patients dossier and health care 
resources used during the period 1999 – 2012. The study sample included 34 chil-
dren aged 3 to 18 years with type 1 diabetes. Seventeen of the children are using 
continuous subcutaneous insulin infusion (CSII) therapy and 17 using intensified 
dosage regime of human insulin. The duration of the disease, diabetic control, HbA1c 
deviation scores, height and weight were observed. Cost of pharmacotherapy, test 
strips were calculated and compared with the therapeutic outcomes in both studied 
groups. The average improvement of HbA (1c) after the CSII introduction was chosen 
as therapeutic outcome. Results: Subcutaneous insulin infusion (CSII) systems are 
not a standard treatment for the Bulgarian children; they are of a limited usage and 
are not reimbursed. From the 34 children with diabetes type 1 observed 17 were on 
CSII (mean age 10 years, mean duration of diabetes - 7 years, average usage of CSII - 3 
years). The test stripes costs 533 Euro/ year and their average cost according to the 
duration of the disease is 3779.45 Euro since diagnosis. The blood glucose monitor-
ing system costs 20 Euro and for the duration of the disease - 4.96 Euro per patient 
per year. The CSII price is 3896 Euro and it costs 1292 euro per patient per year. The 
average improvement of HbA (1c) after the CSII introduction is 1.85. In the group 
treated while human insulin the average cost per children is 925 Euro and improve-
ment of HbA (1c) human insulin is 0.28 for the same period. ConClusions: The 
treatment with CSII leads to significant improvement in glycemic control compared 
to the treatment with human insulin at the comparable costs.
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objeCtives: The rising prevalence of overweight and obesity has led to an increase 
in related metabolic disorders; most notably t2dm. We sought to determine how 
the cost of medication for this condition varies within a cohort of patients attend-
ing Galway University Hospital, according to age, gender, BMI and co-morbidity 
status. Methods: We identified a subgroup of 185 adult type 2 diabetes patients 
attending our university hospital-based diabetes clinic, for whom detailed informa-
tion about drug therapy and comorbidities (obesity, hypertension, dyslipidaemia) 
was available. We modelled the lifetime costs of medications for each patient, taking 
account of age, gender and comorbidity. The analysis compares the lifetime cost of 
medication of those patients who are obese relative to those who are overweight 
and of those with fewer to those with more co-morbidities; specifically obesity, 
hypertension and dyslipidaemia. Results: We found that obesity is associated with 
a higher cost of medication relative to being overweight. Those with a BMI range of 
35-39.9 had the highest mean cost of medication, costing on average € 615 more than 
those who are overweight (p< .01). The highest cost of medication was associated 
with those aged 50-65- non-significant. Among those having all three co-morbidities 
compared to those having only t2dm there was a significant difference in the cost 
of medication costing on average an extra € 418 (p< .05). ConClusions: These 
results suggest that the health economic costs associated with t2dm are differential 
with respect to the BMI status of affected individuals. These findings are of use in 
understanding the drug related burden of illness associated with obesity, t2dm and 
also the burden associated with being obese when one has t2dm compared to not 
being obese and having it. This study generated interesting data which will need to 
be replicated in larger prospective multicentre cohort studies.
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objeCtives: It has been shown that people with diabetes have a high prevalence of 
microvascular (neuropathy, nephropathy, retinopathy, diabetic angiopathy) and mac-
rovascular (hypertension, stroke, myocardial infarction, heart failure and coronary 
artery disease) complications leading to hospitalizations. The objective of the present 
study is to evaluate the cost of hospitalizations due to micro- and macrovascular 
complications in an observed cohort of 433 patients with type 1 and 2 diabetes treated 
with insulin. Methods: The evaluation is based on data from a 6 months com-
bined retrospective and prospective observational study. People were separated in two 
groups depending on the type of diabetes and further into subgroups depending on 
the reason of hospitalization. The total costs for each subgroup of people were calcu-
lated and compared to the total costs of treatment for the observed period. Results: 
In the group of people with type 2 diabetes (n= 255) 128 people with complications 
were observed, whereas in people with type 1 diabetes it was only 70 people out of 
178. The cost of hospitalizations in the type 2 diabetes group was in total 35 367 EUR 
for the people enrolled in the 6 months study with the following division of reported 
reasons: (general) diabetes- 43%, microvascular complications- 16%, and macrovas-
